期刊论文

Regulate Effect of Zhuanggu Zhitong Prescription on the Balance of OPG/RANKL to Anti-osteoporosis

中文

中国现代应用药学

1007-7693

2017

34

7

938-942

10.13748/j.cnki.issn1007-7693.2017.07.002

国家自然科学基金项目（81273816） 清远市科技专项项目（2016A020）

本校为第一机构

目的研究壮骨止痛方对去卵巢骨质疏松大鼠骨保护素（osteoprotegerin,OPG）和NF-？B受体活化因子（receptor activator of NF-？B,RANK）/RANK配体（RANK ligand,RANKL）的影响,探讨其抗骨质疏松的作用机制。方法 72只SD大鼠按体质量随机抽出假手术组12只,造模组60只,造模组采用双侧去卵巢法造模,假手术组只切除卵巢周围相应等量的脂肪。术后造模组大鼠按体质量随机分为模型组、壮骨止痛方高剂量组（13.2 g·kg^（-1））、中剂量组（6.6 g·kg^（-1））、低剂量组（3.3 g·kg^（-1））和戊酸雌二醇组,每组12只。术后第5天开始药物干预,模型组和假手术组给予相应体积的纯净水,持续13周。给药结束...

OBJECTIVE To explore the effect of Zhuanggu Zhitong Prescription on the osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANKL) in ovariectomized rats and investigate its mechanism in anti-osteoporosis. METHODS The 72 SD rats were randomly divided into sham group and model group, the model group rats were ovariectomized and the sham group rats were excised equal weight fat. After the modeling, the rats were randomly divided into model group, Zhuanggu Zhitong Prescription high-dose group (13.2 g·kg~(-1)), middle-dose group (6.6 g·...